therapeutics-话题@MedSci

#therapeutics#

68篇内容 | 2528人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1350843, encodeId=c06f135084309, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Alimentary Pharmacology Therapeutics：经腹电刺激可以改善功能性便秘妇女的症状 , objectType=article, longId=191615, objectId=8a2219161574, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a2219161574, replyNumber=0, likeNumber=41, createdTime=2020-04-08, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a2219161574, moduleTitle=Alimentary Pharmacology Therapeutics：经腹电刺激可以改善功能性便秘妇女的症状 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a2219161574)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350842, encodeId=e1cd13508429d, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Alimentary Pharmacology Therapeutics：丙酸氟替卡松治疗嗜酸性食管炎的安全性和耐受性分析 , objectType=article, longId=191614, objectId=431c191614eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=431c191614eb, replyNumber=0, likeNumber=97, createdTime=2020-04-08, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=431c191614eb, moduleTitle=Alimentary Pharmacology Therapeutics：丙酸氟替卡松治疗嗜酸性食管炎的安全性和耐受性分析 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=431c191614eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350841, encodeId=46531350841b1, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=FDA批准了Agile Therapeutics每周一次的避孕贴片Twirla, objectType=article, longId=188270, objectId=e6841882e006, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6841882e006, replyNumber=0, likeNumber=62, createdTime=2020-02-19, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6841882e006, moduleTitle=FDA批准了Agile Therapeutics每周一次的避孕贴片Twirla, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6841882e006)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350840, encodeId=2ec913508408e, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=KSQ Therapeutics发现潜在活性优于PD-1的基因靶标，可用于开发针对性的工程化肿瘤浸润淋巴细胞（eTIL）治疗难治性实体瘤, objectType=article, longId=187862, objectId=f68418e862d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f68418e862d3, replyNumber=0, likeNumber=50, createdTime=2020-02-13, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f68418e862d3, moduleTitle=KSQ Therapeutics发现潜在活性优于PD-1的基因靶标，可用于开发针对性的工程化肿瘤浸润淋巴细胞（eTIL）治疗难治性实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f68418e862d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350839, encodeId=2bae13508399d, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Autolus Therapeutics公布其CD19/CD22双靶CAR-T细胞疗法在大B细胞淋巴瘤中的阳性临床数据, objectType=article, longId=187159, objectId=649918e159e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=649918e159e2, replyNumber=0, likeNumber=141, createdTime=2020-02-03, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=649918e159e2, moduleTitle=Autolus Therapeutics公布其CD19/CD22双靶CAR-T细胞疗法在大B细胞淋巴瘤中的阳性临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=649918e159e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350838, encodeId=91d3135083823, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功, objectType=article, longId=186029, objectId=4575186029eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4575186029eb, replyNumber=0, likeNumber=50, createdTime=2020-01-11, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4575186029eb, moduleTitle=ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4575186029eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350837, encodeId=4e02135083ee7, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Northsea Therapeutics融资4000万美元开发鱼油衍生物，治疗非酒精性脂肪性肝炎, objectType=article, longId=186009, objectId=83751860095e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83751860095e, replyNumber=0, likeNumber=87, createdTime=2020-01-11, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83751860095e, moduleTitle=Northsea Therapeutics融资4000万美元开发鱼油衍生物，治疗非酒精性脂肪性肝炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83751860095e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350836, encodeId=bb63135083643, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Bicycle Therapeutics宣布与英国癌症研究中心合作开发新型肿瘤免疫学候选药物——多价CD137激动剂BT7401, objectType=article, longId=185937, objectId=58ff18593e64, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58ff18593e64, replyNumber=0, likeNumber=63, createdTime=2020-01-10, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58ff18593e64, moduleTitle=Bicycle Therapeutics宣布与英国癌症研究中心合作开发新型肿瘤免疫学候选药物——多价CD137激动剂BT7401, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58ff18593e64)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350835, encodeId=e5901350835d5, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Cerebral Therapeutics获得3500万美元的B轮融资，以开展其癫痫候选药CT-010的2b期临床, objectType=article, longId=185936, objectId=463f1859360b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=463f1859360b, replyNumber=0, likeNumber=85, createdTime=2020-01-10, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=463f1859360b, moduleTitle=Cerebral Therapeutics获得3500万美元的B轮融资，以开展其癫痫候选药CT-010的2b期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=463f1859360b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350834, encodeId=f7f8135083469, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Leap Therapeutics将DKK1单抗DKN-01亚洲开发权利许可给百济神州，用于与PD-1单抗联用, objectType=article, longId=185777, objectId=0711185e771a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0711185e771a, replyNumber=0, likeNumber=55, createdTime=2020-01-07, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0711185e771a, moduleTitle=Leap Therapeutics将DKK1单抗DKN-01亚洲开发权利许可给百济神州，用于与PD-1单抗联用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0711185e771a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350833, encodeId=04a41350833b7, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Iterum Therapeutics宣布完成口服Sulopenem治疗尿道感染的III期临床试验注册, objectType=article, longId=185461, objectId=e368185461fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e368185461fe, replyNumber=0, likeNumber=69, createdTime=2020-01-01, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e368185461fe, moduleTitle=Iterum Therapeutics宣布完成口服Sulopenem治疗尿道感染的III期临床试验注册, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e368185461fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350832, encodeId=22a61350832c1, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Abeona Therapeutics的ABO-102基因疗法治疗罕见病，获得欧洲药品管理局的PRIME指定, objectType=article, longId=185054, objectId=f497185054c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f497185054c2, replyNumber=0, likeNumber=82, createdTime=2019-12-23, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f497185054c2, moduleTitle=Abeona Therapeutics的ABO-102基因疗法治疗罕见病，获得欧洲药品管理局的PRIME指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f497185054c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350831, encodeId=149313508316d, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Northwestern大学将针对白癜风的DNA药物专利转让给Temprian Therapeutics, objectType=article, longId=183457, objectId=66ca18345eec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66ca18345eec, replyNumber=0, likeNumber=52, createdTime=2019-11-24, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66ca18345eec, moduleTitle=Northwestern大学将针对白癜风的DNA药物专利转让给Temprian Therapeutics, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66ca18345eec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350830, encodeId=e13713508306c, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Levo Therapeutics的鼻内卡贝缩宫素治疗Prader-Willi综合症，获得FDA的快速通道指定, objectType=article, longId=183450, objectId=33641834504d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33641834504d, replyNumber=0, likeNumber=54, createdTime=2019-11-24, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33641834504d, moduleTitle=Levo Therapeutics的鼻内卡贝缩宫素治疗Prader-Willi综合症，获得FDA的快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33641834504d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350829, encodeId=a22e13508297b, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=CARsgen Therapeutics公司的多发性骨髓瘤CAR-T细胞疗法喜获FDA的孤儿药物指定, objectType=article, longId=178782, objectId=c6a71e8782a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6a71e8782a5, replyNumber=0, likeNumber=108, createdTime=2019-09-05, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6a71e8782a5, moduleTitle=CARsgen Therapeutics公司的多发性骨髓瘤CAR-T细胞疗法喜获FDA的孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6a71e8782a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350828, encodeId=2988135082878, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Finch Therapeutics融资5300万美元，推进其微生物疗法预防艰难梭菌感染, objectType=article, longId=178220, objectId=66231e822026, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66231e822026, replyNumber=0, likeNumber=0, createdTime=2019-08-28, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66231e822026, moduleTitle=Finch Therapeutics融资5300万美元，推进其微生物疗法预防艰难梭菌感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66231e822026)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350827, encodeId=ce39135082e41, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Onconova Therapeutics和Mission Bio合作推进基于单细胞基因组学的精准肿瘤临床试验, objectType=article, longId=177566, objectId=4cb81e756687, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cb81e756687, replyNumber=0, likeNumber=60, createdTime=2019-08-15, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cb81e756687, moduleTitle=Onconova Therapeutics和Mission Bio合作推进基于单细胞基因组学的精准肿瘤临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cb81e756687)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350826, encodeId=5a22135082645, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=MC2 Therapeutics完成了MC2-01治疗斑块型银屑病患者欧盟III期头对头研究的患者入组, objectType=article, longId=177305, objectId=15131e730596, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15131e730596, replyNumber=0, likeNumber=76, createdTime=2019-08-10, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15131e730596, moduleTitle=MC2 Therapeutics完成了MC2-01治疗斑块型银屑病患者欧盟III期头对头研究的患者入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15131e730596)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350825, encodeId=d638135082579, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Knight Therapeutics的Neratinib成为第一个在加拿大获批的抗HER2疗法，用于激素受体阳性、HER2阳性早期乳腺癌的延长辅助治疗, objectType=article, longId=175669, objectId=17911e5669f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17911e5669f5, replyNumber=0, likeNumber=63, createdTime=2019-07-19, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17911e5669f5, moduleTitle=Knight Therapeutics的Neratinib成为第一个在加拿大获批的抗HER2疗法，用于激素受体阳性、HER2阳性早期乳腺癌的延长辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17911e5669f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350824, encodeId=e3e51350824cc, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, objectTitle=Applied Therapeutics宣布启动AT-007在半乳糖血症中的I/II期研究, objectType=article, longId=172183, objectId=c32b1e21837d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c32b1e21837d, replyNumber=0, likeNumber=64, createdTime=2019-06-27, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c32b1e21837d, moduleTitle=Applied Therapeutics宣布启动AT-007在半乳糖血症中的I/II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c32b1e21837d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

therapeutics

2020-05-29

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Alimentary Pharmacology Therapeutics：经腹电刺激可以改善功能性便秘妇女的症状

2020-04-08

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Alimentary Pharmacology Therapeutics：丙酸氟替卡松治疗嗜酸性食管炎的安全性和耐受性分析

2020-04-08

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

FDA批准了Agile Therapeutics每周一次的避孕贴片Twirla

2020-02-19

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

KSQ Therapeutics发现潜在活性优于PD-1的基因靶标，可用于开发针对性的工程化肿瘤浸润淋巴细胞（eTIL）治疗难治性实体瘤

2020-02-13

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Autolus Therapeutics公布其CD19/CD22双靶CAR-T细胞疗法在大B细胞淋巴瘤中的阳性临床数据

2020-02-03

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功

2020-01-11

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Northsea Therapeutics融资4000万美元开发鱼油衍生物，治疗非酒精性脂肪性肝炎

2020-01-11

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Bicycle Therapeutics宣布与英国癌症研究中心合作开发新型肿瘤免疫学候选药物——多价CD137激动剂BT7401

2020-01-10

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Cerebral Therapeutics获得3500万美元的B轮融资，以开展其癫痫候选药CT-010的2b期临床

2020-01-10

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Leap Therapeutics将DKK1单抗DKN-01亚洲开发权利许可给百济神州，用于与PD-1单抗联用

2020-01-07

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Iterum Therapeutics宣布完成口服Sulopenem治疗尿道感染的III期临床试验注册

2020-01-01

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Abeona Therapeutics的ABO-102基因疗法治疗罕见病，获得欧洲药品管理局的PRIME指定

2019-12-23

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Northwestern大学将针对白癜风的DNA药物专利转让给Temprian Therapeutics

2019-11-24

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Levo Therapeutics的鼻内卡贝缩宫素治疗Prader-Willi综合症，获得FDA的快速通道指定

2019-11-24

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

CARsgen Therapeutics公司的多发性骨髓瘤CAR-T细胞疗法喜获FDA的孤儿药物指定

2019-09-05

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Finch Therapeutics融资5300万美元，推进其微生物疗法预防艰难梭菌感染

2019-08-28

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Onconova Therapeutics和Mission Bio合作推进基于单细胞基因组学的精准肿瘤临床试验

2019-08-15

一叶知秋 (审核中...)

前往app查看评论内容

#therapeutics#

MC2 Therapeutics完成了MC2-01治疗斑块型银屑病患者欧盟III期头对头研究的患者入组

2019-08-10

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Knight Therapeutics的Neratinib成为第一个在加拿大获批的抗HER2疗法，用于激素受体阳性、HER2阳性早期乳腺癌的延长辅助治疗

2019-07-19

zhaojie88 (审核中...)

前往app查看评论内容

#therapeutics#

Applied Therapeutics宣布启动AT-007在半乳糖血症中的I/II期研究

2019-06-27

科室
- - 订阅+
  - 更多科室
工具
服务